Search
Learn how new clinical trials at MSK are helping make cancer care at home a reality.
VEXAS syndrome is a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men over 50. Now, MSK researchers are shedding new light on its mechanisms and laying the groundwork for potential targeted treatments.
An MSK clinical trial found that participating in integrative therapy classes online could benefit cancer patients in active treatment, not only by reducing fatigue, anxiety, and depression but also lowering hospitalization rates.
En un ensayo clínico de MSK se descubrió que participar en clases de terapia integral en línea podría beneficiar a los pacientes que padecen cáncer y reciben tratamiento activo, no solo porque reduce la fatiga, la ansiedad y la depresión, sino también porque disminuye las tasas de hospitalización.
A gift from the estate of renowned fashion designer Geoffrey Beene will enable MSKCC to launch an ambitious research initiative to be known as the Geoffrey Beene Cancer Research Center.
Learn how MSK is Improving patients’ quality of life with less toxic treatments.
A new tool called optogenetics is revealing clues about the function of a promising experimental therapy derived from stem cells.
Sloan Kettering Institute’s (SKI) Alexander Gitlin, MD, PhD of Memorial Sloan Kettering Cancer Center (MSK) was recognized as a winner of the National Institutes of Health (NIH) Director’s Early Independence Award.
Learn about some of the latest treatments for thyroid cancer and clinical trials that have been led by researchers from MSK.
In a proof-of-concept study, researchers at MSK and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.